Journal article
Towards a biological staging model for operable non-small cell lung cancer
Abstract
Non-small cell lung cancer is the most common cause of cancer-related death in North America and Europe. Despite improvements in the diagnosis and treatment of the disease the prognosis remains poor, the overall 5-year survival being 4-14%. An increased understanding of the molecular biology of the disease may identify novel targets for drug development. We evaluated epidermal growth factor receptor (EGFR), HER-2/neu, matrix metalloproteinase …
Authors
O'Byrne KJ; Cox G; Swinson D; Richardson D; Edwards JG; Lolljee J; Andi A; Koukourakis MI; Giatromanolaki A; Gatter K
Journal
Lung Cancer, Vol. 34, , pp. s83–s89
Publisher
Elsevier
Publication Date
December 2001
DOI
10.1016/s0169-5002(01)00352-x
ISSN
0169-5002
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGenes, erbB-2HumansLung NeoplasmsMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MicrocirculationMiddle AgedNeoplasm StagingNeovascularization, PathologicPrognosisProto-Oncogene Proteins c-bcl-2Retrospective StudiesTumor Suppressor Protein p53